Coya Therapeutics Inc

COYANASDAQ · USD
3.00USD0.00 (0.00%)
122

Coya Therapeutics Inc (COYA) Historical Volatility

COYA's 30 day historical volatility is 75.12%, in the 94th percentile of readings over the past year. This is a high percentile, meaning Coya Therapeutics Inc shares have swung far more than usual. COYA's 30 day implied volatility sits at 436.97%, with an IV Rank of 90.08%, leaving IV 361.85 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 16, 2026.

Read more

Tracking COYA historical volatility helps you see how much Coya Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, COYA's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor COYA 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. COYA's 30 day historical volatility, or COYA HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing COYA's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases.

Historical Volatility

HV Percentile
94thHV Percentile
High

Historical movement is elevated versus the past year. The stock has been unusually active.

Historical Volatility (30d)75.12%

HV Percentile94th

Implied Volatility (30d)436.97%

IV Rank90.08%

IV Minus HV+361.85%

As of Nov 16, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 16, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →